Refractory Cancer Clinical Trials

21 recruiting

Refractory Cancer Trials at a Glance

22 actively recruiting trials for refractory cancer are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 15 trials, with the heaviest enrollment activity in New York, Heidelberg, and Bonn. Lead sponsors running refractory cancer studies include Australian & New Zealand Children's Haematology/Oncology Group, GV20 Therapeutics, and Immatics Biotechnologies GmbH.

Browse refractory cancer trials by phase

Treatments under study

About Refractory Cancer Clinical Trials

Looking for clinical trials for Refractory Cancer? There are currently 21 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 1Phase 2

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Refractory CancerB-cell LymphomaB-cell Malignancy+1 more
BeOne Medicines80 enrolled50 locationsNCT06634589
Recruiting
Phase 2

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer

Prostate CancerRefractory Cancer
Wake Forest University Health Sciences50 enrolled2 locationsNCT04337580
Recruiting
Phase 1Phase 2

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics US, Inc.375 enrolled21 locationsNCT03686124
Recruiting
Phase 2

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Refractory CancerRelapsed CancerLarge Cell Lymphoma, Diffuse
Dipenkumar Modi32 enrolled4 locationsNCT05852717
Recruiting
Phase 2

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Refractory CancerPrimary Central Nervous System LymphomaRelapsed Cancer+1 more
Baptist Health South Florida15 enrolled1 locationNCT05681195
Recruiting
Phase 1

A Study of Avutometinib for People With Solid Tumor Cancers

Solid TumorSolid Tumor, AdultNeuroblastoma+12 more
Memorial Sloan Kettering Cancer Center23 enrolled2 locationsNCT06104488
Recruiting
Phase 1Phase 2

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Head and Neck CancerRecurrentRelapse+1 more
UNC Lineberger Comprehensive Cancer Center33 enrolled1 locationNCT06096038
Recruiting
Phase 1Phase 2

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 1Phase 2

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Refractory CancerRecurrent CancerChildhood Cancer+2 more
Australian & New Zealand Children's Haematology/Oncology Group90 enrolled14 locationsNCT06208657
Recruiting
Phase 1

Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

Metastatic Solid TumorSolid Tumor, AdultRefractory Cancer
Sairopa B.V.130 enrolled7 locationsNCT05856981
Recruiting
Phase 4

Plan Development for Giving Teclistamab in the Outpatient Setting

Multiple MyelomaRefractory CancerRelapsed Cancer
University Health Network, Toronto15 enrolled1 locationNCT06251076
Recruiting
Phase 1

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

MelanomaHead and Neck Squamous Cell CarcinomaMetastatic Cancer+16 more
Memorial Sloan Kettering Cancer Center56 enrolled7 locationsNCT05859074
Recruiting
Phase 1Phase 2

Study of GV20-0251 in Participants With Solid Tumor Malignancies

Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)+2 more
GV20 Therapeutics350 enrolled3 locationsNCT07070518
Recruiting
Phase 1Phase 2

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

Metastatic CancerSolid TumorUnresectable Solid Tumor+3 more
Spago Nanomedical AB90 enrolled2 locationsNCT06184035
Recruiting
Phase 1Phase 2

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH145 enrolled24 locationsNCT05958121
Recruiting
Phase 1

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

CancerSolid Tumor, AdultRefractory Cancer+1 more
Immatics Biotechnologies GmbH95 enrolled23 locationsNCT05359445
Recruiting
Phase 1

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

Solid TumorsRefractory Cancer
Chiome Bioscience Inc.70 enrolled2 locationsNCT07016997
Recruiting
Phase 1Phase 2

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Solid Tumor, AdultCutaneous MelanomaRefractory Cancer+3 more
GV20 Therapeutics365 enrolled13 locationsNCT05669430
Recruiting
Phase 1

Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)

MalignancyCancerRefractory Cancer+1 more
CytoMed Therapeutics Pte Ltd12 enrolled1 locationNCT05302037
Recruiting

Precision Medicine for Every Child With Cancer

Refractory CancerChildhood CancerChildhood Brain Tumor+3 more
Australian & New Zealand Children's Haematology/Oncology Group3,500 enrolled11 locationsNCT05504772